KOP Therapeutics Corp. — Form D/A
KOP Therapeutics Corp. of VANCOUVER, A1, a company, filed a Form D amendment with the SEC on 2019-12-19. The offering totals $114K, of which $114K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2019-12-19
- Form: D/A
- Accession: 0001683168-19-004036
- Industry: Biotechnology
- Exemptions: 06c
- Total offering: $114K
- Amount sold: $114K
- Investors: 2
- Date of first sale: 2019-10-22
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-353470
Issuer
- Name: KOP Therapeutics Corp.
- CIK: 0001793824
- Entity type: Corporation
- Jurisdiction: BRITISH COLUMBIA, CANADA
- Incorporated: 2018
- Address: SUITE 404 - 815 HORNBY STREET, VANCOUVER, A1, V6Z 2E6
- Phone: 6047718332
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Mark Richard Redcliffe | Director | VANCOUVER, A1 |
| Mark Richard Redcliffe | Executive Officer | VANCOUVER, A1 |
| Tibor Fancis Gajdics | Director | VANCOUVER, A1 |
| Tibor Fancis Gajdics | Executive Officer | VANCOUVER, A1 |
| Ian Hollis Mann | Director | VANCOUVER, A1 |
| Marco Andres Strub | Director | VANCOUVER, A1 |
Other filings by this issuer (2)
More